however, because this was a retrospective target trial emulation with a relatively small number of events, it is not yet practice-changing and should instead be viewed as a signal that supports further research into the role of GLP-1 receptor agonists in epileptogenesis. Limitations and future directions The authors emphasised that the study design was observational, despite using advanced statistical methods to emulate a clinical trial
The bottom line Basal insulin and GLP-1 combinations like Xultophy and Soliqua can be a great option for managing type 2 diabetes
In February 2025 , the FDA declared the semaglutide shortage resolved and began restricting compounding ( [62] )
Cons : Some people find it more sensitive, especially around the belly button
Other symptoms then appear, including nausea, vomiting, weakness, sweating, and hypotension